Valuation: Recursion Pharmaceuticals, Inc.

Market Cap 1.56B 1.37B 1.26B 1.16B 2.19B 151B 2.24B 15.07B 5.93B 73.72B 5.87B 5.74B 254B P/E 2026 *
-3.39x
P/E 2027 * -3.15x
Enterprise Value 1.12B 979M 903M 832M 1.57B 108B 1.6B 10.79B 4.25B 52.82B 4.21B 4.11B 182B EV / Sales 2026 *
17.3x
EV / Sales 2027 * 15.3x
Free-Float
96.67%
Yield 2026 *
-
Yield 2027 * -
1 day-2.48%
1 week-17.28%
Current month-19.75%
1 month-8.82%
3 months-22.09%
6 months-36.94%
Current year-28.00%
1 week 2.93
Extreme 2.93
3.54
1 month 2.93
Extreme 2.93
4.09
Current year 2.77
Extreme 2.77
5.24
1 year 2.77
Extreme 2.77
7.18
3 years 2.77
Extreme 2.77
16.1
5 years 2.77
Extreme 2.77
37.61
10 years 2.77
Extreme 2.77
42.81
Manager TitleAgeSince
Chief Executive Officer 43 2025-12-31
Director of Finance/CFO 48 2024-11-19
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 44 2013-11-03
Director/Board Member 62 2013-11-03
Director/Board Member 37 2016-08-31
Date Insider Type Main position Quantity % Market Cap.
7/7/26 Sell

Founder

-40,000 0.0076%
7/1/26 Free

Founder

3,747 0.0007%
7/1/26 Free

Director

5,109 0.0010%
Change 5-day change 1-year change 3-year change Capi.($)
-2.48%-17.28%-49.57%-78.39% 1.56B
+0.24%-1.54%+52.85%+71.85% 53.83B
-7.17%-4.39%+42.72%+73.32% 52.1B
+0.80%-6.31%+5.62%+417.78% 23.48B
-0.09%-0.01%-16.85%-15.41% 23.13B
-5.95%-2.58%+29.53%-9.47% 19.36B
-1.14%+0.03%+31.67%-30.65% 17.56B
-5.16%-7.00%+168.44%+314.96% 15.2B
-6.91%-5.83%+25.17%+644.30% 14.83B
+0.43%-1.03%+25.75%+189.74% 14.06B
Average -2.74%-4.09%+31.53%+157.80% 23.51B
Weighted average by Cap. -2.80%-2.45%+38.95%+141.65%

Financials

2026 *2027 *
Net sales 64.74M 56.57M 52.21M 48.12M 90.7M 6.23B 92.71M 624M 245M 3.05B 243M 238M 10.51B 83.76M 73.2M 67.55M 62.26M 117M 8.07B 120M 807M 318M 3.95B 315M 308M 13.6B
Net income -453M -396M -365M -337M -635M -43.65B -649M -4.37B -1.72B -21.38B -1.7B -1.66B -73.59B -525M -459M -423M -390M -735M -50.55B -752M -5.06B -1.99B -24.76B -1.97B -1.93B -85.23B
Net Debt -443M -387M -357M -330M -621M -42.69B -635M -4.27B -1.68B -20.91B -1.66B -1.63B -71.97B -285M -249M -230M -212M -400M -27.47B -409M -2.75B -1.08B -13.46B -1.07B -1.05B -46.32B
Logo Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.
Employees
600
Date Price Change Volume
26-07-17 US$2.945 -2.48% 19,353,220
26-07-16 US$3.020 -8.76% 40,174,578
26-07-15 US$3.310 -0.90% 19,429,100
26-07-14 US$3.340 +1.21% 25,658,546
26-07-13 US$3.300 -7.30% 24,497,736
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
2.945USD
Average target price
7.250USD
Spread / Average Target
+146.18%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RXRX Stock